Cogent reports Q2 net loss $96.4M; bezuclastinib PDUFA dates set for Nov/Dec 2026

Cogent Biosciences, Inc.

Net loss $96.4M vs $73.5M in Q2 2025; R&D $70.8M, G&A $31.8M.
Cash $792.3M at June 30, 2026; pro forma $865.9M with $73.6M ATM proceeds, funds into late 2028.
FDA accepted NDA for bezuclastinib+sunitinib in GIST with priority review; PDUFA Nov 30, 2026.
AdvSM NDA submitted June 30; NonAdvSM PDUFA Dec 30, 2026; APEX trial 65% ORR.
PEAK trial: HR 0.50, mPFS 16.5 vs 9.2 months, ORR 46% vs 26%.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.